Good news for scleroderma lung disease. Abstract OP0017 shows less decline in SSc ILD with nintedanib v placebo. Half on MMF in both groups. Less decline if on MMF but still 40% reduction in active v placebo in both subsets and combination seemed safe. @RheumNow #EULAR2019 https://t.co/1CJ4sggZsj